These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19073965)

  • 41. High-content micronucleus assay in genotoxicity profiling: initial-stage development and some applications in the investigative/lead-finding studies in drug discovery.
    Mondal MS; Gabriels J; McGinnis C; Magnifico M; Marsilje TH; Urban L; Collis A; Bojanic D; Biller SA; Frieauff W; Martus HJ; Suter W; Bentley P
    Toxicol Sci; 2010 Nov; 118(1):71-85. PubMed ID: 20631060
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of division-arrested cells for cell-based high-throughput screening and profiling.
    Digan ME; Pou C; Niu H; Zhang JH
    J Biomol Screen; 2005 Sep; 10(6):615-23. PubMed ID: 16103416
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multi-pathway cellular analysis of compound selectivity.
    Hancock MK; Lebakken CS; Wang J; Bi K
    Mol Biosyst; 2010 Oct; 6(10):1834-43. PubMed ID: 20593073
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adopting a practical statistical approach for evaluating assay agreement in drug discovery.
    Sun D; Whitty A; Papadatos J; Newman M; Donnelly J; Bowes S; Josiah S
    J Biomol Screen; 2005 Aug; 10(5):508-16. PubMed ID: 16093560
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inverse Virtual Screening allows the discovery of the biological activity of natural compounds.
    Lauro G; Masullo M; Piacente S; Riccio R; Bifulco G
    Bioorg Med Chem; 2012 Jun; 20(11):3596-602. PubMed ID: 22537682
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An efficient rapid system for profiling the cellular activities of molecular libraries.
    Melnick JS; Janes J; Kim S; Chang JY; Sipes DG; Gunderson D; Jarnes L; Matzen JT; Garcia ME; Hood TL; Beigi R; Xia G; Harig RA; Asatryan H; Yan SF; Zhou Y; Gu XJ; Saadat A; Zhou V; King FJ; Shaw CM; Su AI; Downs R; Gray NS; Schultz PG; Warmuth M; Caldwell JS
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3153-8. PubMed ID: 16492761
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Integrated technology platform protein kinases for drug development in oncology.
    Sachsenmaier C; Schächtele C
    Biotechniques; 2002 Oct; Suppl():101-6. PubMed ID: 12395934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Development of PAK1 kinase inhibitors with "in silico" modeling methods].
    Ferenc B; Csaba SK; Zoltán G; Jeno M; Zoltán V; György K; László O
    Acta Pharm Hung; 2010; 80(4):155-61. PubMed ID: 21404476
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of a high-throughput scintillation proximity assay for the identification of C-domain translational initiation factor 2 inhibitors.
    Delle Fratte S; Piubelli C; Domenici E
    J Biomol Screen; 2002 Dec; 7(6):541-6. PubMed ID: 14599352
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-throughput virtual screening of proteins using GRID molecular interaction fields.
    Sciabola S; Stanton RV; Mills JE; Flocco MM; Baroni M; Cruciani G; Perruccio F; Mason JS
    J Chem Inf Model; 2010 Jan; 50(1):155-69. PubMed ID: 19919042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protein Kinase Selectivity Profiling Using Microfluid Mobility Shift Assays.
    Drueckes P
    Methods Mol Biol; 2016; 1439():143-57. PubMed ID: 27316993
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The feasibility of application of reverse docking method to the selectivity studies of protein kinase inhibitors].
    Liu TL; Xie HZ; Wei YQ; Yang SY
    Yao Xue Xue Bao; 2009 Jul; 44(7):758-63. PubMed ID: 19806916
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Virtual screening to successfully identify novel janus kinase 3 inhibitors: a sequential focused screening approach.
    Chen X; Wilson LJ; Malaviya R; Argentieri RL; Yang SM
    J Med Chem; 2008 Nov; 51(21):7015-9. PubMed ID: 18844338
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Redesigning kinase inhibitors to enhance specificity.
    Crespo A; Zhang X; Fernández A
    J Med Chem; 2008 Aug; 51(16):4890-8. PubMed ID: 18680272
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Classification of kinase inhibitors using a Bayesian model.
    Xia X; Maliski EG; Gallant P; Rogers D
    J Med Chem; 2004 Aug; 47(18):4463-70. PubMed ID: 15317458
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chemical genetic approaches to kinase drug discovery.
    Gallion SL; Qian D
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):638-45. PubMed ID: 16159026
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors.
    Lin WH; Song JS; Chang TY; Chang CY; Fu YN; Yeh CL; Wu SH; Huang YW; Fang MY; Lien TW; Hsieh HP; Chao YS; Huang SF; Tsai SF; Wang LM; Hsu JT; Chen YR
    Anal Biochem; 2008 Jun; 377(1):89-94. PubMed ID: 18358823
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A simple set-and-mix assay for screening of protein kinase inhibitors in cell lysates.
    Asami Y; Oishi J; Kitazaki H; Kamimoto J; Kang JH; Niidome T; Mori T; Katayama Y
    Anal Biochem; 2011 Nov; 418(1):44-9. PubMed ID: 21802396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.